GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vac... ( ATLANTA Sept. 24 /- GeoVax Labs I...)

GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial

Date:9/24/2007

ATLANTA, Sept. 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX)

On September 21, 2007, Merck & Co., Inc. announced their candidate AIDS vaccine failed to provide protection in a human study designed to test for efficacy.

In this Merck trial involving high risk volunteers, an equal number of people received either placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be stopped because it was not reaching its efficacy endpoints.

Merck has stopped further vaccinations but will continue to follow volunteers in the trial. The Merck trial was being carried out in conjunction with the HIV Vaccine Trials Network (HVTN), a prestigious trial network funded by the US National Institutes of Health.

Don Hildebrand, GeoVax's President and CEO, commented, "We, along with the rest of the scientific community, are disappointed in the clinical failure of Merck's HIV vaccine trial. We all share the same goal of finding a safe and effective vaccine to address the devastation of the HIV/AIDS epidemic. We, however, would like to take this opportunity to highlight important differences between our vaccine technology and the technology used in the Merck trial."

GeoVax AIDS vaccines advancing in human trials represent a significantly different vaccine approach, vaccine composition and results to date than the Merck vaccine.

1) Prototypes for the GeoVax vaccines were selected from a series of trials in non-human primates for their ability to protect against the development of AIDS when vaccinated individuals were administered an AIDS causing virus. At each major step along the development pathway, GeoVax vaccines providing the best protection against AIDS were moved forward.

2) GeoVax AIDS vaccines demonstrated excellent protective results in non- human primate models, much better protective results than reported for Merck's vaccine in similar models. GeoVax AIDS vaccines pro
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

Post Your Comments:

GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vac...( ATLANTA Sept. 24 /- GeoVax Labs I...),Health